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Background: Clinical trials are essential for the advancement of cancer treatments; how-
ever, participation by patients is suboptimal. Currently, there is a lack of synthesized 
qualitative review evidence on the patient experience of trial entry from which to further 
develop decision support. The aim of this review is to synthesise literature reporting 
experiences of participants when deciding to enrol in a cancer clinical trial in order to inform 
practice.
Methods: A systematic review and meta-synthesis of qualitative studies were conducted to 
describe the experiences of adult cancer patients who decided to enrol in a clinical trial of an 
anti-cancer treatment.
Results: Forty studies met eligibility criteria for inclusion. Three themes were identified 
representing the overarching domains of experience when deciding to enrol in a cancer trial: 
1) need for trial information; (2) trepidation towards participation; and (3) justifying the 
decision. The process of deciding to enrol in a clinical trial is one marked by uncertainty, 
emotional distress and driven by the search for a cure.
Conclusion: Findings from this review show that decision support modelled by shared 
decision-making and the quality of a shared decision needs to be accompanied by tailored or 
personalised psychosocial and supportive care. Although the decision process bears simila-
rities to theoretical processes outlined in decision-making frameworks, there are a lack of 
supportive interventions for cancer patients that are adapted to the clinical trial context. 
Theory-based interventions are urgently required to support the specific needs of patients 
deciding whether to participate in cancer trials.
Keywords: advanced cancer, qualitative, guideline development, consolidated framework 
for implementation research
Introduction
Clinical trials play a central role in the advancement of medical care, ensuring 
effectiveness and safety in new health-care interventions and treatments.1 In oncol-
ogy, cancer treatments are evaluated on a pathway of development, testing and 
implementation, relying on results from clinical trials to substantiate their thera-
peutic efficacy.2 Despite more than 2300 clinical trials initiated across the globe in 
2016 alone,3 consistent estimates suggest fewer than one in twenty adults with 
cancer enrol in a trial.2 Although as many as 70% of individuals diagnosed with 
cancer are willing to participate in trials4 barriers to participation have persisted 
over the last twenty years.5 Hence, there appears to be a gap between the numbers 
of individuals willing to enrol in a clinical trial and the percentage of those who 
actually participate. Barriers to participant recruitment and retention in oncology 
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trials are well reported and include, but are not limited to, 
treatment uncertainty;6 financial barriers;7 logistical con-
cerns such as protocol stringency;8 and a lack of resources 
for patients and clinicians to support clinical trial enrol-
ment and retention.7 Findings from a systematic review of 
barriers to participant recruitment report similar challenges 
persisting in studies published from 1995 to 2012.9
One approach to addressing these barriers has been the 
development and application of decisions aids in the clin-
ical trial setting. A Cochrane review of decision aids in 
this context outlined the application of informational- 
based decisional tools targeting outcomes such as decisio-
nal regret, knowledge, conflict, anxiety, trial participation 
and attrition.10 The review found only low-level evidence 
for effectiveness of these decision aids, and further noted 
that process outcomes, such as decisional involvement, 
values and risk expectations, were not considered. In addi-
tion, a deeper consideration of more patient-centred out-
comes for such studies was proposed. In this regard, the 
decision to enrol in a clinical trial of a cancer treatment is 
influenced by a range of extrinsic and intrinsic factors with 
the process both complex, personal and potentially signifi-
cant given it can have life-altering consequences.11 Studies 
report that for individuals with cancer, these factors can 
include, but are not limited to, increased hope about dis-
ease prognosis;12,13 the chance to compare interventions;14 
enhanced therapeutic relationships with specialist 
clinicians;12 relief from the financial burden of care in 
some cases;14 and improved overall survival.15 
Additionally, making the decision to participate in a clin-
ical trial is particularly difficult where proposed treatments 
are new or novel and information about their safety, effi-
cacy or effectiveness is lacking when compared to con-
ventional treatments.9
Despite the need to understand the context in which 
trial participation is made and how to support individuals 
with cancer, there is a lack of synthesized review evidence 
on both the patient experience of deciding to enrol in a 
clinical trial and how best to support them. To date, a 
review by Gregerson et al16 on clinical trial decision 
making in advanced cancer with a focus on end of life 
decisions is the only review that examines experiences of 
patients in this area. To our knowledge, there is no review- 
based evidence reporting the experiences and subsequent 
supportive care and decision needs of cancer patients 
deciding to enrol in a clinical trial. Accordingly, we under-
took a systematic review of qualitative studies describing 
the experiences of adult cancer patients deciding to enrol 
in a clinical trial of an anti-cancer treatment.
Methods
The aim of this review was to synthesise literature report-
ing experiences of participants deciding to enrol in a 
clinical trial of anti-cancer treatment. For the purposes of 
this study, active cancer treatment includes the provision 
of anti-cancer therapy to patients with active cancer. For 
example, chemotherapy, immunotherapy, radiotherapy and 
surgery. This study will systematically review all aspects 
of participant enrolment in active anti-cancer treatment 
trials. The study proposes to develop and exhaustive qua-
litative understanding of the experience leading up to 
consenting to a clinical trial in order to identify the indi-
vidual factors, barriers and enablers that may influence the 
decision to enrol in a clinical trial of an anti-cancer 
treatment.
Search Strategy
A comprehensive search strategy sought all eligible quali-
tative studies from the following electronic databases: 
PubMed, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), PsycINFO, Scopus and ProQuest 
Theses & Dissertations. No date restriction was applied. 
The search strategy for each database or platform consists 
of both Medical Subject Headings (MeSH) and free-text 
words (as appropriate) (see Table 1).
Eligibility Criteria
We included studies that reported the experiences of patients 
deciding to enrol in clinical trial of anti-cancer treatment. For 
this reason, qualitative studies on the experiences of this 
cohort were included. Studies were included if they were 
peer-reviewed, published in English and included adult 
human patients only. Dissertations and theses were also 
included; however none were identified. Full-text articles 
were also included. Studies were excluded if they were 
nested and reported quantitative data only. We also excluded 
nested studies within cancer-related interventions that were 
not for anti-cancer treatment. Grey literature was not 
included in the review (eg, government or professional orga-
nisation documents) (see Table 2 for the inclusion and exclu-
sion criteria).
Study Selection
Succeeding the search, all identified citations were gath-
ered and uploaded into EndNote database (EndNote X8.1) 
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and duplicate records removed. Titles and abstracts were 
then screened by two independent reviewers (BV, NR) for 
assessment against the inclusion criteria. These two 
reviewers independently screened 100% each of the arti-
cles. A list of potential studies for inclusion was circulated 
between BV and NR. Disagreements on study eligibility 
were resolved through discussion.
The full text of selected studies was retrieved following 
the initial screening and assessed in detail. Authors were 
contacted in cases of incomplete data or irretrievable articles. 
If the article was irretrievable (ie, not accessible from any 
source or from the authors), the study was excluded. The full 
text of each selected article was screened by the two inde-
pendent authors (NR [100%], BV [100%]) to determine 
eligibility against the inclusion and exclusion criteria.
To ensure that all relevant studies were included, a 
manual search of citations and references of eligible stu-
dies was also conducted. Resulting references were 
exported separately and provided to the two reviewers 
(BV, NR) for independent review. Where necessary, 
study authors were contacted for missing information. To 
ensure impartiality the inclusion and exclusion criteria was 
constantly referred to (see Table 2). The results of the 
search are reported according to the PRISMA guidelines 
Table 1 Search Strategy
Database Search Strategy
PUBMED ((((((randomized controlled trial[Title]) OR clinical trial[Title]) OR trial[Title]) OR randomized trial[Title]) AND 
Humans[Mesh] AND English[lang])) AND (((“cancer”[Title]) AND (((((((((motivation[Title]) OR recruit[Title) OR 
decision[Title]) OR attitude[Title]) OR “focus group”[Title]) OR “qualitative”[Title]) OR participant[Title]) OR enrol 
[Title]) OR reason)) 
(1285)
CINAHL TI Cancer AND TI (motivation OR recruit OR decision OR attitude OR “focus group” OR “qualitative” OR 
participant OR enrol OR reason) AND TI (“randomized controlled trial” OR “randomised controlled trial” OR 
“clinical trial” OR “trial” OR “randomized trial”) 
(622)
PsycInfo (S1 AND S2 AND S3) 
S1 TI (cancer) 
S2 TI(motivation or recruit or decision or attitude or “focus group” or “qualitative” or participant or enrol or reason) 
S3 TI(“randomized controlled trial” or “randomised controlled trial” or “clinical trial” or “trial” or “randomized 
trial”) 
(161)
Scopus (TITLE (cancer) AND TITLE (motivation OR recruit OR decision OR attitude OR “focus group” OR “qualitative” OR 
participant OR enrol OR reason) AND TITLE (“randomized controlled trial” OR “randomised controlled trial” OR 
“clinical trial” OR “trial” OR “randomized trial”)) AND (LIMIT-TO (LANGUAGE, “English”)) 
(910)
ProQuest Theses & 
Dissertations
(ti(randomised controlled trial) OR ti(randomized controlled trial) OR ti(clinical trial) OR (trial) OR (randomised 
trial)) AND (ti(cancer)) AND (ti(attitude) OR ti(motivation) OR ti(reason) OR ti(decision) OR ti(enrol) OR ti(focus 
group) OR ti(qualitative) OR ti(recruit) OR ti(participant)) 
(351)
Table 2 Study Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
● Qualitative studies investigating decisions/experiences of enrolment in a clinical 
trial reporting qualitative data
● Studies reporting any aspect of participant enrolment in a trial of active cancer 
treatment.
● Peer-reviewed studies in English
● Adult human patients only
● Dissertations and theses
● Nested studies reporting quantitative data only
● Nested studies of cancer-related studies without anti- 
cancer treatment
● Grey literature (eg, government or professional orga-
nisation documents)
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for systematic reviews, detailing the number of papers 
identified by the search strategy and the number of papers 
that were included and excluded are stated. Any disagree-
ments that arose between the reviewers were resolved 
through discussion. A PRISMA flow diagram of the 
study selection is outlined in Figure 1.17
Data Analysis and Synthesis
Data were extracted by two independent authors (BV, NR) 
for a random 10% (selected by simple random sampling) of 
the included studies. For the remaining studies, one author 
(BV) extracted the data and checked by a second author 
(NR). Any disagreements were resolved through discussion. 
The PDF files (or equivalent) of manuscripts were download 
and imported into NVivo and data extracted.
Data were synthesised by utilising a thematic analysis 
approach, which enables extraction of concepts and hypoth-
eses from multiple qualitative studies.18 Data were coded using 
NVivo and identified themes were categorised and presented as 
a narrative. All aspects of the thematic analysis were reviewed 
against the data. This involved several readings of each paper. 
The analysis and its explanations were repeatedly discussed 
among the researchers until consensus was reached.19 The 
findings from the systematic review are described using 
meta-synthesis. Qualitative meta-synthesis aims to synthesise 
qualitative data to further develop identified themes and pro-
vide a more extensive interpretation of the findings.20 In this 
qualitative review, quotations were included (see Table 3) to 
allow readers to assess the validity of the domains.
Patient and Public Involvement
No patients from the included studies were involved in this 
review.
Quality Assessment
Two independent reviewers (BV, NR) performed quality 
assessment. Each included study was critically appraised 
using a quality assessment tool drawn from the Standard 
Figure 1 PRISMA flow diagram.  
Notes: Moher D, Liberati A, Tetzlaff J, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535. 
doi:10.1136/bmj.b253517
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Table 3 Themes and Quotations
Themes Sub-Themes Quotes
Need for Trial 
Information
Reactions to a 
worsening cancer 
situation
“You know I just couldn’t believe you know, just the shock. The shock”.12 
“My family and I were so scared when the doctor said ‘cancer’; I don’t think I heard anything else that 
was said. I really couldn’t think about a trial at that time. I had to digest how scared I was to know I had 
cancer.”41 
“I heard the words lung cancer and I felt I was kicked in the gut . . .. I was terrified”.40 
“[I would] have to control my emotions first, before I could make a decision”.31 
“ . . . He said ‘cancer’ straight away, well, it terrifies you”.29 
“And that was the first time he ever mentioned that word (cancer) to me. So that was kind of a shock 
and I was by myself”.34 
“I just can’t throw my hands up and say, ‘I give up’, I mean, ‘cause you got, you know, you got kids”.28 
“It was panic city. I have never been more afraid of anything in my life”.45
Need for Health 
Professional 
Support
“My mind was like on overload. I felt like I went to nursing school in a real short amount of time”.24 
“I thought well (the doctor) was pushing me (to consent) when he/she shouldn’t have been . . . and that really 
annoyed me . . . . . . he/she is quite abrupt . . . I felt isolated”.38 
“I think you are so stunned really you don’t always ask questions that you probably should have done. I still 
think sometimes I just try and shut it away. I don’t know whether this is normal”.27 
“Sometimes is seems like they [the doctors] are dealing with us, I don’t know, like animals”.31 
“Being pressured put me off – obviously they need to get started, I understand that, but you need time to think 
about the diagnosis let alone to think about whether to take part in a trial”.46
Need for Tailored 
Information
“As I said it doesn’t give you any information as to whether what they feel would be adequate for you, if 
it was on a banding system . . . ”.24 
“It did not tell you anything because it was all in medical words and that it was purely a means of the 
doctors covering themselves”.27 
“[Patients] . . . need to get somebody that can talk to them in terms that, you know, fit their mental 
capacity”.28 




Fear “It brings up fear, it is frightening—animal testing and the unknown and pain”.41 
“It was absolutely overwhelming for me. I was scared. I’d wake up in the morning with fear”.40 
“There is uncertainty with new drugs; there is no guarantee”.36 
“It’s like walking on a plank and you don’t know where the end is – you know whether you are going to drop 
off nor not”26 
“I was afraid to take a chance. If I only have a limited time left I don’t want to waste my time with research 
where the outcome is unknown”.41 
“Testing, it’s scary. It is like you are a guinea pig and have no control over what will happen”.41 
“It’s like walking on a plank and you don’t know where the end is – you know whether you are going to drop 
off or not”.26 
“The biggest barrier to me, the one and only really, is fear, because cancer is fear itself and it compounds it. 
You don’t want to put yourself at risk in any way whatsoever. And its absolute terror you see”.46
Leaving Treatment 
to Chance
“I want to decide for myself and not let luck or others decide for me”.36 
“You’re gonna put my name in a hat and draw us out and see which one I’m gonna get?”58 
“The only thing I don’t understand is when you are pulled out of the computer . . . that’s when the 
problem started (I withdrew) ’you will be picked out at random’ was what they said . . . and I had no 
more control . . . I got out”.38 
“It’s like putting them in a hat and rolling them around and pulling one out and saying, “go for the 
operation””.63 
“To me it’s your life, to let a machine decide, oh no, that didn’t appeal”.63
(Continued)
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Quality Assessment Criteria for Evaluating Primary 
Research Papers from a Variety of Fields21 with the addi-
tional of: a statement of human research ethics committee 
approval. To assess the reliability and validity of included 
studies, studies had to meet the criteria provided in 
Table 4.21 Studies were independently screened and scored 
(0–22) by two reviewers (BV, NR). The two reviewers also 
referred to the Consolidated Criteria for Reporting Quality 
Research (COREQ)22 guidelines to discuss study quality 
and appraise the standard of evidence. Each paper could 
achieve a maximum score of 22. On each criterion two 
points were awarded for yes, one for partial and zero for 
no. All studies were judged to be either of high quality 
(scores of 17–20 points), adequate (scores of 11–16 points) 
or weak (scores of 0–10 points). High-quality studies were 
subsequently included in the final analysis (Table 5). 
Table 3 (Continued). 
Themes Sub-Themes Quotes
Sensing No Other 
Alternative
“Listen love . . . when you get to my age and you have a choice of living or dying, you pick to live. Believe 
me or not!”.24 
“What I wanted most was to have as much removed as possible to avoid death at an early age”12 
“If I am stage four, I do not mind trying”.54 
“If it was gonna help me get through it, you know, even the slim chance of it making it better . . . Yeah, 
anything I could do to not have to burn or not go through anything, I was willing to try”.39 
“I thought that clinical trials were only for a last resort when you have nothing to lose”.42 
“I can lay down and die, or I can make myself available to the therapies that are available to me”.56 
“I feel I have no choice. I do want to get well, if that’s possible, and then you have to catch at all the 
straws you can find”.53 
“[The] alternative was death and [I] didn’t want to die”.64 
“[It’s] the best option, I had to do something”.64 
“I can lay down and die, or I can make myself available to the therapies that are available to me”.56 
“Not everyone gets the change to take part in something like this”.26
Justifying the 
Decision
Need for Social 
Validation
“So it (support groups) wasn’t nearly as easy as I had imagined . . . they weren’t there when I need them. 
They really weren’t”.12 
“I was informed by Dr. X and then I talked to my husband. I looked at my husband and said “We have to 
join this”—and so we did”.54 
“Family experience definitely affected how I chose treatments since I had a sister die of breast cancer 
and had two cousins die of it in their 30’s”.12 
[My] youngest [daughter] got her mind set on this one particular . . . thing. She found that particular one 
[clinical trial] and she is just determined that that’s going to be the cure”.28




“I came here for only the best . . . If he came to me, my doctor, and said let’s do a clinical trial, I would do 
it. I trust him”.51 
“I would [participate in a clinical trial] if my doctor recommended and I trust him, I would participate 
because I trust his medical advice”.33 
“To be honest and truthful I am going to tell you I was asked and said yes and that was it. I don’t think I 
thought anymore”.27 
“I felt they knew what they were doing, and I trusted them completely. And I certainly haven’t gone back 
on that. I felt that I’m in the best hands I could be in”.28 
“Participating in a clinical trial is very much about trusting, that these people will not put me at 
unnecessary or irresponsibly risk . . . They will take care of me . . . if the confidence is broken it will be 
very dangerous to participate in trials . . ..”37 
“I would choose whatever had been recommended to me by the doctor or doctors . . .. I think that 
applies to pretty well everything . . . ”.61 
“You trust an authority, don’t you? And I kind of believe that the doctors here, who are like specialised 
in this sphere of diseases, of course you trust them. Who else would you trust?.”53 
“I would choose whatever had been recommended to me by the doctor or doctors . . . I think that 
applies to pretty well everything . . . ”.61
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Discrepant scores were resolved through discussion and 
consensus. The main methodological issues included 
inadequate explanation of the researcher-participant rela-
tionship, how this may have influenced conclusions and 
inadequate explanation of analytical rigour.
Results
Of the 40 studies reviewed, 11 were of local and 3 of 
advanced cancers; 19 included mixed cancer types and 7 
did not specify. The phase of the trial was reported incon-
sistently throughout studies with 4 Phase I and 6 Phase III; 
11 studies reported patients across a number of trials at 
different phases and 19 were not specified. All studies 
were conducted in countries with highly developed 
health-care systems such as USA (21), UK (10), Sweden 
(2), Netherlands (2), Denmark (2), England (1), Canada 
(1) and Singapore (1). Following meta-synthesis, three 
themes were identified representing the overarching 
domains of experience in deciding to participate in a 
cancer trial: (1) need for trial information; (2) trepidation 
towards participation; and (3) justifying the decision. 
Selected quotations reported in primary studies are 
included in Table 3 to demonstrate the correlation between 
the identified themes and patients’ perspectives on treat-
ment decision making. A summary of the included studies 
is provided in Table 5.
Need for Trial Information
Consideration of trial participation was reported in most 
studies (25/40) to stem from “reactions to a worsening 
cancer situation”.12,23–46 This situation could be described 
as a rapid change in health status or prognosis. Throughout 
the context of distress, confusion, uncertainty and illness, 
patients desperately attempt to identify and understand all 
of the appropriate treatment options available to them.41
Reactions to a Worsening Cancer Situation
Once cancer patients were informed their cancer was wor-
sening, they experienced feelings of shock, fear and 
disbelief.27,28,33,44,45 “You know I just couldn’t believe it 
you know, just the shock. The shock”12 (see Table 3). As 
patients tried to comprehend this change in health status, 
treatment options were introduced, including the invitation 
to take part in a clinical trial.12,47 Due to the overwhelming 
emotions at this stage of their cancer trajectory, patients 
expressed a desire for their physician to consider their 
emotional concerns and offer support before providing 
them with trial information.30 The patients’ distressed 
state affected the amount of information they absorbed 
and impeded their ability to make health-related 
decisions.23,40,45,48 Making the decision to enrol in a clin-
ical trial of an active anti-cancer treatment is complex and 
personal for all cancer patients. Being confronted with trial 
information and not receiving enough emotional support 
during this time, led to decisional conflict.49
Need for Health Professional Support
The interaction and information exchange between physician 
and patient was reported as a significant issue in most of the 
included studies (31/40).12,23–28,30–37,39–46,48,50–55 Patients 
experienced one-sided, dismissed or rushed conversations 
with physicians, resulting in feelings of alienation, pressure, 
coercion and an absence in autonomy.37,41,45
(. . .) I thought well (the doctor) was pushing me (to con-
sent) when he/she shouldn’t have been . . . and that really 
annoyed me . . . . . . he/she is quite abrupt . . . () I felt 
isolated37 
This hindered most patients’ desire and ability to make 
treatment-related decisions (see Table 3).37 In some cases, 
patient autonomy and ethical practice were not upheld, 
often due to a perceived lack of time to consider informa-
tion about the trial.37,56 Patients clearly stated that if phy-
sicians acknowledged their concerns, offered reassurance 
and took the time to listen, they felt they could then trust 
that the physicians recommendation on clinical trial 
participation.30 Patients also reinforced the importance of 
having enough time to comprehend a cancer prognosis and 
filter through treatment information before making 
decisions.12,45,47
Being pressured put me off – obviously they need to get 
started, I understand that, but you need time to think about 
the diagnosis let alone to think about whether to take part 
in a trial.45 
Need for Tailored Information
The treatment information patients received was mostly 
described as confusing (25/40).23,24,26–34,36,37,41–48,52,53,57,58 
Written information was reported as lacking in detail23 and 
difficult to read in terms of sentence length and word 
complexity.26,43 “It did not tell you anything because it was 
all in medical words and that it was purely a means of the 
doctors covering themselves”26 (see Table 3). Most partici-
pants used internet-based sources to better understand the 
material they received or to obtain information described in 
more layman’s terms.30,31,33,44,56 Even with this initiative, 
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confusion was still evident and the level of knowledge about 
trial basics was considerably low amongst most cancer 
patients.26,27,37,53,59,60 “[Patients] . . . need to get somebody 
that can talk to them in terms that, you know, fit their mental 
capacity”.27 This lack of trial understanding demonstrated a 
clear disconnect between trialists and their patients, to the 
extent that not all patients understood their position in the 
consent process. Some even believed that withdrawal from a 
trial was impossible, affecting treatment decision-making.37
(Once randomised) you couldn’t volunteer for the other 
(treatment) because you only got that if you went into the 
trial and got away with it through randomisation.37 
Trepidation Towards Participation
A substantial finding across reported studies (29/40) was 
patients experience of trepidation, most commonly expressed 
as “fear”.12,14,25,27–29,31–33, 35–46,48,50,51,54,57,60–62 This was 
frequently associated with cancer diagnosis, prognosis and 
treatment options.29,40 Trepidation towards participation was 
associated with fear of cancer diagnosis, prognosis and treat-
ment options.29,40 Common reasons for trepidation included 
cancer fatalism,35 the lack of time to decide on treatment,40 
concern about the “unknown”47 and the possibility of a 
negative response to the trial.47 Patients with a history of 
cancer, not only expressed uncertainty but the fear of cancer 
reoccurrence as well.12,27,40 These factors formed a mental 
barrier and delayed the decision to enrol in a clinical 
trial.12,27,35,47
Participants described not wanting to lose control, feel 
isolated, alienated or powerless during decision-making.33,37 
Common statements associated with the idea of participating 
in a clinical trial included “I am scared”,29 “I am nervous” 
about joining a trial,47 concerns about feeling like a “guinea 
pig”, or an “experiment”, “trial and error”,32 “feeling alone” 
and “having no say”34,37,45,46,48,57,61 (see Table 3). Another 
primary influence in considering treatment options was 
patients’ fear of potential adverse side effects associated 
with clinical trial participation27,29,33,43,44,46. This included 
both the known and unknown risks intrinsic in clinical trial 
medicines.27,35 There was a clear need for patients to con-
sider the potential side effects and its impact on future quality 
of life (QOL) against the therapeutic advantages of the trial.48 
Patients desired and suggested that their health-care provi-
ders offer detailed discussions and deliver general and spe-
cific information about clinical trials in order to improve their 
understanding of the risk-to-benefit ratio in clinical trial 
enrolment.35,40,54
Leaving Treatment to Chance
Before enrolling in a clinical trial, most participants 
expressed concerns about the process of randomisation 
and wanted to know the treatment group in which they 
would be placed.14,48,54,62 As depicted in Table 3, the idea 
of randomisation made most patients feel uncomfortable or 
stressed46 and made some unwilling to join a clinical trial.35 
Patients wanted to make an informed choice and felt 
“unpleasant” leaving treatment decisions to chance.31,35 
There was a general lack of knowledge about the concept 
of random assignment and the need for comparing two 
different treatments.32,46,57 Patients struggled to make 
sense of their involvement in the trial process while ques-
tioning scientific principles.37
Sensing No Other Alternative
Evident in 30 out of the 40 included studies, was patients 
tendency to simplify their treatment options by evaluating 
them in terms of life versus death, regardless of fear or 
randomisation.12,23,25,27–30,32–36,38–44,46,48,50–54,60,61,63 
There was a predisposition to perceive the active pursuit of 
treatment as the only option available and there was “no real 
choice” to make.23,25,28,30,43,52,63 The use of the term “last 
resort” was used by many patients offered Phase III clinical 
trials.32,35,42,50,63 As validated in Table 3, the majority of 
participants suggested that treatment options presented 
were considered with reference to the goal of living longer 
and hopefully abating cancer.43,44,46,60 This goal seemed to 
influence the way in which the options were comprehended, 
evaluated and experienced within decision making.12 For 
most, the offer to participate in a clinical trial provided 
some form of hope.25,26,28,33,43,46,51–53,61 Hope was viewed 
as complex, affected by spirituality and faith, interpersonal 
relationships, trust, positivity and vital to the coping 
process.29,48,51,53 When patients sensed they had no other 
alternative they tended to make the treatment decision 
quickly. Patients frequently described, “having already 
made their mind up”, “seeing trial as just a natural thing to 
do”, “going with their gut feelings” and even suggesting “it 
never entered my mind to say no”.23,25,28,47,52,53
Justifying the Decision
Patient decision-making processes are influenced by the 
knowledge and support received from their family, friends 
and physician. This is viewed as important in order to justify 
their decision about clinical trial participation.56 Many parti-
cipants further expressed a moral obligation to participate in 
a clinical trial for altruistic purposes14,23,25,28,30,35,46,52,55,61 
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and the desire to assist in furthering clinical 
research.23,52,54,63,64
Need for Social Validation
Twenty-nine out of the forty studies suggest that patients’ 
approach to decision making is influenced by their sociodemo-
graphic, social and cultural backgrounds, their experiences 
with health-care services and their relationships with their 
health-care providers.14,23,25–29,31,33,34,36–44,48,51–56,60,61,63 The 
opinion and knowledge of patients’ physician, family and 
friends were predominantly noted as important in decision- 
making and facilitators for clinical trial enrolment.35 Brown 
(2013) states that patients actively want to share decisions.48 
The support of family, peers and health professionals was 
fundamental in being able to comprehend their diagnosis, 
treatment options and treatment experience.12
With the established difficulty in decision-making and 
processing treatment information, many patients wished to 
seek the opinion of others and/or hear from previous trial 
participants’ experiences of clinical trial treatment.23,27 
Patients stated they would try and contact previous clinical 
trial participants to enquire about “what they tried and 
what they used”56 to assist them in understanding the 
actuality of trial participation and inform decision- 
making.27,31,42,56 Patients also wanted to be aware of sup-
port groups before enrolment.12 Participants who heard 
about successful trials emphasised that hearing stories 
allowed them to feel more enthusiastic about the research, 
some even went online and/or approached clinical provi-
ders about trials42 as indicated in Table 3. Speaking with 
previous survivors was verbalised as decision aids, helping 
participants know they were not alone, providing an addi-
tional viewpoint and gave them a sense of feeling 
valued.12,23
Participants sought some form of family involvement 
in the clinical trial decision-making process. This was 
identified as a significant finding across the included stu-
dies (23/40).26–31,33–36,38–40,42–44,46,48,52,53,56,61,63 The 
involvement of family was either to assist patients in 
their search for more information about the trial, help 
them stay informed about the clinical trial process and/or 
support their final decision about treatment. The opinions 
of friends and family was viewed as an important facil-
itator if the opinions were positive and seen as a barrier if 
the opinions were negative.35 To manage this, patients 
selectively involved family members in their decision 
making, engaging with those they shared a strong and 
close relationship or when they had scientific or medical 
training.47,56 Patients also determined when and how to 
share particular types of information. Some reasons for 
excluding family members from discussions about trial 
participation included a desire to avoid creating perceived 
emotional and psychological burdens for family 
members.56
Patients who witnessed friends or family members who 
had experienced cancer, positive and negative results with 
treatment and any long-term outcomes impacted their 
treatment considerations and decision-making.12,29,44 As 
demonstrated in Table 3, some patients stressed the impor-
tance of making decisions in partnership with family mem-
bers, as portrayed in the use of plural pronouns such as 
“we” and “our” in talking about the final decision.56 These 
relationships were essential; family members attended 
appointments, participated in discussions around clinical 
trial enrolment, showed concern, provided physical and 
emotional support, shared expert knowledge and therefore 
influenced the treatment decisions that were made.56
Need for Health Professional Rapport and Validation
Trust in a physician’s recommendation or opinion concerning 
enrolment in a clinical trial was reported as vital in majority 
of included studies (31/40).14,25–37,39–44,47,50,52–56,60,61,63,65 A 
commonly-held belief in one study was that the doctor would 
not offer trial participation if it was not in the patients’ best 
interest.26 Patients indicated that, if they held a long-standing 
relationship and developed trust in their doctors’ medical 
judgment, they would most likely adhere to their doctors’ 
guidance.30,39,50 Being content with decision-making 
appeared to be influenced by the trust, respect and relation-
ships patients had with health-care providers and health-care 
personnel26,28,31,33,36,37,40,42,43,52,55,63 (see Table 3). Enabling 
trust and building rapport over time were identified as an 
important basis to facilitate good communication, willing-
ness to participate in a trial and ultimately affected decision- 
making.14,25,43,55 Participants wanted their physician to be 
honest with them, providing reassurance and clarity through 
quality consultations and discussions.24,37,41,43,50 Trust in the 
doctor, specialists and medical team were crucial in consid-
ering the available treatment options.14,27 This trust, as well 
as trust in local governance, drug development processes and 
government legislation were all viewed as facilitators to 
clinical trial enrolment.35 Patients yearn for the knowledge 
that clinical trials are conducted in an ethical manner and 
cited confidence that adequate care is given during trial 
procedure as facilitators for clinical trial enrolment.35
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Discussion
To our knowledge, this is the only review that comprehen-
sively synthesises evidence from qualitative studies report-
ing the experience of patients deciding whether to enrol in 
a clinical trial. Our findings show that after a cancer 
diagnosis and being invited to enrol in a clinical trial, 
deciding to enrol revolves around the “need for trial infor-
mation”; “trepidation towards participation”; and “justify-
ing the decision”. Our data highlights several points 
among which is an overarching need to better address 
informational and decision-support needs in individuals 
deciding to enrol in a cancer trial.
Firstly, there is a need to improve the way patients are 
informed about clinical trials and supported to make a 
decision that is right for them. Moreover, given the broad 
array of needs voiced by patients across most included 
studies as well as the role of health professionals in meet-
ing them, finding effective decision-support interventions 
should be a priority for health systems and clinical trialists 
everywhere.
Secondly, understanding decision-making in the con-
text of a clinical trial and individuals’ associated needs for 
decision-support should be prioritised. Our findings bear 
similarity to the domains of Charles’ Shared Decision- 
Making Framework66 in which patients make decisions 
in the context of (1) “information exchange”; after (2) 
“deliberation” happens; and towards (3) “deciding on 
treatment to implement”. Given the broad applicability of 
Charles’ framework66 to health contexts, our thematically 
similar results suggest the decision process of enrolling in 
a clinical trial may not be dissimilar to other health-related 
decisions experienced by cancer patients. Instead, where 
the decision-process may differ is context; clinical trials 
present as uncertain and unfamiliar to many participants 
and health professionals lack the interventions that com-
prehensively address informational, psychological and 
decision support needs. For instance, a Cochrane review 
reported inconclusive results on whether individuals who 
were provided with a decision aid experienced changes in 
comprehension and/or uncertainty during decision 
making.10 Recently, decision aids adaptable to the clinical 
trial context have become available via the International 
Patient Decision Aids Standards (IPDAS) Collaboration 
however their effectiveness in the trial context remains 
unknown thus far.67–69
Thirdly, across every theme, participants reported a 
desire for personalised support from the clinician inviting 
them to participate in a trial. The communication style of 
the clinician plays an important role in patients under-
standing of information and willingness to join a trial.70 
Poor communication techniques used by a physician can 
lead to insufficient patient understanding.71 Information 
provision should therefore be tailored to address patients’ 
needs, questions and concerns.70 For trialists and patients, 
addressing prospective participants’ emotional needs, 
actively listening and promoting opportunities to converse 
with, inform, question and interact with each other may 
provide the best mechanism for addressing negative 
aspects of the decision-making experience. It is important 
for clinicians to implement a variety of communication 
strategies to enhance participants understanding of clinical 
trial information.71 Efficacious communication ensures 
participants receive relevant information customised to 
their individual learning requirements and encourages 
informed decision-making.72
A focus for decision support may therefore be on improv-
ing communication skills using a shared decision-making 
framework to structure any proposed intervention. 
According to the IPDAS Collaboration how information is 
presented can have a significant impact on the knowledge 
patients acquire, by affecting patient ability to understand 
and integrate the information.68 These points are supported 
by Nishimura’s 2013 review of interventions for improving 
informed consent in trials insofar as conversational opportu-
nities may lead to enhanced understanding of the study 
among participants, a greater sense of partnering in the 
research process, and heightened rapport between trialists 
and participants.73 The evaluation criteria for assessing the 
quality of patient decision aids as part of the IPDAS 
Collaboration, identified coaching/guidance in deliberation 
and communication as one of twelve broad dimensions in the 
field of patient design and development.74 Patients and phy-
sicians may therefore profit from receiving coaching and 
guidance in order to cultivate high-quality and productive 
two-way communication.74
Fourth, we would argue that the experiences synthe-
sised from the data of 40 included studies show a need for 
interventions that address all facets of the decision-making 
process described herein. Supporting people to learn about 
trials in their preferred way and in view of their own 
circumstances is crucial for any decision support interven-
tion. Participants should also be given the opportunity to 
express their emotions and be provided with the space to 
deliberate about the best course to take for their circum-
stances. Two-way communication that is accompanied by 
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a strong-patient provider relationships, that recognises 
individual preferences and values and incorporates and 
evaluates the use of effective evidence-based information, 
leads to greater treatment satisfaction and positive health 
outcomes.74 Interventions therefore should be multimodal 
to reflect diverse learning styles in the broader community 
while space to make a decision should be better incorpo-
rated into the informed consent process.75 Nevertheless, 
with many failed interventions for supporting the decision 
to enrol in a clinical trial,10 more work is needed to build 
on the process identified in our review and identify ways 
to measure outcomes of decision support and design effec-
tive interventions for cancer survivors deciding whether to 
enrol in a clinical trial.
Strengths and Limitations
We used a carefully designed and systematic search strat-
egy, rigorous inclusion criteria, and a validated quality 
assessment process to determine the merits of our review 
findings. Moreover, several experienced researchers 
reviewed the protocol and were involved in the key phases 
of the review. Additionally, we used a popular and robust 
approach to synthesising qualitative data for systematic 
reviews.18 Our review was limited by being unable to 
access raw qualitative transcripts from any authors identi-
fied for inclusion in the study due to either a lack of ethical 
approval, failure to reply or unavailability of transcripts 
mostly due to the elapsed time of some studies. All of the 
studies were conducted in the health systems of highly 
developed economies. Therefore, there is a limitation that 
these results may not apply to low-and-middle-income 
counties. Additionally, we have included studies that 
have focused on the experiences of patients involved in 
enrolling in a clinical trial however, of note is that six of 
these studies also included interviews of patients who 
subsequently declined clinical trial participation. While it 
was not possible to identify those who declined within the 
data from included studies, we believe the experiences of 
individuals declining to participate in a clinical trial is a 
gap in the literature and should be a topic for further 
research.
Conclusion
Our review findings indicate that the decision to partici-
pate in a clinical trial is an experience marked by complex 
informational, emotional and psychological needs. With a 
lack of evidence on effective interventions, further work is 
needed to design strategies for individuals considering 
whether to enrol in a trial which pair quality decision 
support with effective psychosocial and supportive care.
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